Skip to main content
. Author manuscript; available in PMC: 2016 Oct 21.
Published in final edited form as: Nephron. 2015 Oct 21;131(3):191–201. doi: 10.1159/000441151

Fig. 2.

Fig. 2

a–b. Correlation between mean arterial pressure (MAP) change and kidney function during midodrine/octreotide therapy. The largest MAP change was divided into quartiles and plotted against the subsequent change (1 day following peak MAP change) in serum creatinine (sCr) in patients with hepatorenal syndrome (HRS) treated with midodrine/octreotide in the presumed HRS cohort (n=73) (a) and the definite HRS cohort (n=27) (b). Bar graphs represent mean values and error bars represent 95% CI (means (SD) are shown) * P values for the correlations obtained by generalized linear mixed models (GLMMs), which included adjustment for covariates (i.e., baseline sCr, baseline MAP, days on therapy, and MELD score).